Zydena is under phase 2 clinical studies for portal hypertension
Published: 2008-02-28 06:59:00
Updated: 2008-02-28 06:59:00
Dong-A PharmTech Co., affiliate of Dong-A Pharmaceutical. Co., announced on February 25 that it has initiated a 200 patient, phase 2 clinical study in Europe to investigate the use of Zydena (udenafil), a long-acting phosphodiesterase type 5 inhibitor, for portal hypertension.
Zydean is emergi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
